Explain this page
Arphra AIPlain-English read on Aktis Oncology, Inc.’s valuation06-11today
- Aktis Oncology: Mini-Proteins With A Targeted Punch13d
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 202644d
- Aktis Oncology to Present at the BofA Securities Health Care Conference49d
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)51d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$0.76
-97.36% vs spot
Recommendation
Sell
3 of 4 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $35.33 (+23.10%)
Candlestick · 1Y
Open in chart workstation →AKTS
24.09+9.60%H 24.82L 14.72MA50 18.94MA200 —Avg vol 315K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.26% | +17.86% | +41.10% | +54.05% | +28.13% | +28.13% | +28.13% | +28.13% | +28.13% | +28.13% | +28.13% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$27.40
Bid
$29.27
1 sh
Ask
$31.27
1 sh
Spread
$2.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $1.87M | -$15.14M | $-0.28 |
| Q4 Dec 2024 | $933K | -$12.06M | $-0.23 |
Sector & industry today
LiveSectors
- Real Estate+1.26%
- Utilities+0.96%
- Consumer Cyclical+0.94%
- Energy+0.84%
- Financial Services+0.65%
- Basic Materials-0.11%
- Communication Services-0.40%
- Healthcare-0.41%
- Industrials-0.47%
- Technology-0.80%
- Consumer Defensive-1.00%
Top industries (issuer's industry highlighted)
- Biotechnology+6.56%
- Financial - Mortgages-4.05%
- Home Improvement+3.89%
- Electrical Equipment & Parts+3.88%
- Paper, Lumber & Forest Products+3.53%
- Software - Services-3.30%
- Software - Infrastructure-3.07%
- Financial - Conglomerates+2.62%
- Auto - Dealerships+2.54%
- Luxury Goods+2.47%
- Auto - Recreational Vehicles+2.22%
- REIT - Industrial-2.20%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Aktis Oncology: Mini-Proteins With A Targeted Punchseekingalpha.com·Jun 11, 2026
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026globenewswire.com·May 11, 2026
- Aktis Oncology to Present at the BofA Securities Health Care Conferenceglobenewswire.com·May 06, 2026
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)globenewswire.com·May 04, 2026
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)globenewswire.com·May 04, 2026
Recent analyst activity
DB- Jun 15, 2026GradeStrong BuyAktis Oncology initiated with a Strong Buy at Raymond JamesRaymond James
- Jun 15, 2026PT$40.00Aktis Oncology initiated with a Strong Buy at Raymond JamesRaymond James
- Jun 02, 2026GradeBuy → BuyAktis Oncology price target raised to $35 from $33 at H.C. WainwrightH.C. Wainwright
- Jun 02, 2026PT$35.00Aktis Oncology price target raised to $35 from $33 at H.C. WainwrightH.C. Wainwright
Peers
No peer list available for AKTS.
Total assets
$264.89M
Total debt
$11.55M
Cash & equiv
$37.78M
Operating CF
-$64.13M
Free cash flow
-$73.71M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $6.5M | -$74.68M | -$63.73M | $-1.19 | -980.93% |
| FY 2024 | $1.49M | -$52.05M | -$43.98M | $-1.26 | -2957.63% |
| FY 2023 | $0 | -$34.79M | -$28.64M | $-0.82 | — |
| FY 2022 | $0 | -$19.76M | -$17.93M | $-0.51 | — |